Comparative Pharmacology
Head-to-head clinical analysis: ELIQUIS versus ELIQUIS SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIQUIS versus ELIQUIS SPRINKLE.
ELIQUIS vs ELIQUIS SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apixaban is a selective, reversible direct inhibitor of factor Xa (FXa). It inhibits both free and clot-bound FXa, thereby reducing thrombin generation and thrombus formation.
Apixaban is a selective, reversible, direct inhibitor of factor Xa, inhibiting both free and clot-bound factor Xa, thereby reducing thrombin generation and thrombus formation.
5 mg orally twice daily for most indications; 2.5 mg orally twice daily for patients with at least two of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
5 mg orally twice daily; for certain patients meeting criteria (age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL), dose is 2.5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 9–14 hours) after multiple oral doses; supports twice-daily dosing. In elderly patients, half-life may extend by ~30%.
Terminal half-life 12 hours (range 9-14h) in healthy adults; prolonged to approximately 24 hours in moderate renal impairment (CrCl 15-30 mL/min).
Approximately 27% of the dose is excreted renally as unchanged drug; 25% is excreted as metabolites via the biliary/fecal route (total fecal excretion ~50% of absorbed dose). Renal clearance accounts for ~27% of total clearance; also a substrate for P-glycoprotein (P-gp).
Renal 27% unchanged; hepatic metabolism via CYP3A4/5 and CYP-independent hydrolysis, with fecal elimination as metabolites.
Category C
Category C
Factor Xa Inhibitor
Factor Xa Inhibitor